JPWO2016204217A1 - Biocompatible materials, coating compositions, coating films and articles - Google Patents
Biocompatible materials, coating compositions, coating films and articles Download PDFInfo
- Publication number
- JPWO2016204217A1 JPWO2016204217A1 JP2017525289A JP2017525289A JPWO2016204217A1 JP WO2016204217 A1 JPWO2016204217 A1 JP WO2016204217A1 JP 2017525289 A JP2017525289 A JP 2017525289A JP 2017525289 A JP2017525289 A JP 2017525289A JP WO2016204217 A1 JPWO2016204217 A1 JP WO2016204217A1
- Authority
- JP
- Japan
- Prior art keywords
- biocompatible material
- cells
- coating
- article
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000560 biocompatible material Substances 0.000 title claims abstract description 63
- 238000000576 coating method Methods 0.000 title claims description 81
- 239000011248 coating agent Substances 0.000 title claims description 73
- 239000008199 coating composition Substances 0.000 title claims description 22
- 229920001577 copolymer Polymers 0.000 claims abstract description 67
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 31
- -1 vinyl compound Chemical class 0.000 claims abstract description 29
- 229920002313 fluoropolymer Polymers 0.000 claims abstract description 18
- 239000004811 fluoropolymer Substances 0.000 claims abstract description 18
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims description 34
- 238000004113 cell culture Methods 0.000 claims description 31
- 229960000074 biopharmaceutical Drugs 0.000 claims description 25
- 238000001179 sorption measurement Methods 0.000 claims description 16
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 claims description 11
- 238000000465 moulding Methods 0.000 claims description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 56
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 41
- 238000000034 method Methods 0.000 description 38
- 241000588724 Escherichia coli Species 0.000 description 27
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 20
- 239000000178 monomer Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 230000001464 adherent effect Effects 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- 229920002799 BoPET Polymers 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical group FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 102000004506 Blood Proteins Human genes 0.000 description 10
- 108010017384 Blood Proteins Proteins 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000012503 blood component Substances 0.000 description 8
- 210000002242 embryoid body Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 210000003850 cellular structure Anatomy 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000000961 QCM-D Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000005757 colony formation Effects 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 5
- 238000004528 spin coating Methods 0.000 description 5
- OPQYOFWUFGEMRZ-UHFFFAOYSA-N tert-butyl 2,2-dimethylpropaneperoxoate Chemical compound CC(C)(C)OOC(=O)C(C)(C)C OPQYOFWUFGEMRZ-UHFFFAOYSA-N 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000005266 casting Methods 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012237 artificial material Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 2
- HQGPZXPTJWUDQR-UHFFFAOYSA-N 1-ethenyl-5-methylpyrrolidin-2-one Chemical compound CC1CCC(=O)N1C=C HQGPZXPTJWUDQR-UHFFFAOYSA-N 0.000 description 2
- SVKPOEIKEBFDDN-UHFFFAOYSA-N 1-ethenylazetidin-2-one Chemical compound C=CN1CCC1=O SVKPOEIKEBFDDN-UHFFFAOYSA-N 0.000 description 2
- PBGPBHYPCGDFEZ-UHFFFAOYSA-N 1-ethenylpiperidin-2-one Chemical compound C=CN1CCCCC1=O PBGPBHYPCGDFEZ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical group C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000007641 inkjet printing Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229920001567 vinyl ester resin Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- SUTQSIHGGHVXFK-UHFFFAOYSA-N 1,2,2-trifluoroethenylbenzene Chemical compound FC(F)=C(F)C1=CC=CC=C1 SUTQSIHGGHVXFK-UHFFFAOYSA-N 0.000 description 1
- DURRSEGFTCZKMK-UHFFFAOYSA-N 1-prop-2-enylpyrrolidin-2-one Chemical compound C=CCN1CCCC1=O DURRSEGFTCZKMK-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QMIWYOZFFSLIAK-UHFFFAOYSA-N 3,3,3-trifluoro-2-(trifluoromethyl)prop-1-ene Chemical compound FC(F)(F)C(=C)C(F)(F)F QMIWYOZFFSLIAK-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710145752 Serine recombinase gin Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 238000012662 bulk polymerization Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 229950008486 carperitide Drugs 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000012674 dispersion polymerization Methods 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 238000009503 electrostatic coating Methods 0.000 description 1
- 238000007610 electrostatic coating method Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 108010002601 epoetin beta Proteins 0.000 description 1
- 229960004579 epoetin beta Drugs 0.000 description 1
- 229950002346 epoetin kappa Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 229960002907 follitropin beta Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010089296 galsulfase Proteins 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 102000056614 human NPPA Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940038490 inactivated hepatitis a vaccine Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 108010050259 insulin degludec Proteins 0.000 description 1
- 229960004225 insulin degludec Drugs 0.000 description 1
- 229940052319 insulin degludec and insulin aspart Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229940095009 interferon gamma-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 210000003125 jurkat cell Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108700008455 metreleptin Proteins 0.000 description 1
- 229960000668 metreleptin Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- PNLUGRYDUHRLOF-UHFFFAOYSA-N n-ethenyl-n-methylacetamide Chemical compound C=CN(C)C(C)=O PNLUGRYDUHRLOF-UHFFFAOYSA-N 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- HLOKOWLRHKENST-UHFFFAOYSA-N n-methyl-n-prop-2-enylformamide Chemical compound O=CN(C)CC=C HLOKOWLRHKENST-UHFFFAOYSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 229950010676 nartograstim Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 108700037519 pegvisomant Proteins 0.000 description 1
- 229960002995 pegvisomant Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012673 precipitation polymerization Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VPJDULFXCAQHRC-UHFFFAOYSA-N prop-2-enylurea Chemical compound NC(=O)NCC=C VPJDULFXCAQHRC-UHFFFAOYSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000002145 thermally induced phase separation Methods 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229950009227 trafermin Drugs 0.000 description 1
- 108010078749 trafermin Proteins 0.000 description 1
- 238000001721 transfer moulding Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
- C08F214/18—Monomers containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Surgery (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Virology (AREA)
- Materials For Medical Uses (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Laminated Bodies (AREA)
- Paints Or Removers (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
改善された生体適合性を有する新規生体適合性材料を提供する。フルオロポリマーからなる生体適合性材料であって、上記フルオロポリマーは、フルオロオレフィンとアミド結合を有する重合性ビニル化合物との共重合体であり、フルオロオレフィン単位が65〜5モル%であり、アミド結合を有する重合性ビニル化合物単位が35〜95モル%であることを特徴とする生体適合性材料である。Provided are novel biocompatible materials having improved biocompatibility. A biocompatible material comprising a fluoropolymer, wherein the fluoropolymer is a copolymer of a fluoroolefin and a polymerizable vinyl compound having an amide bond, the fluoroolefin unit is 65 to 5 mol%, and an amide bond It is a biocompatible material characterized in that the polymerizable vinyl compound unit having 35 to 95 mol%.
Description
本発明は、生体適合性材料に関する。また、本発明は、上記生体適合性材料からなるコーティング組成物、コーティング膜及び物品にも関する。 The present invention relates to biocompatible materials. The present invention also relates to a coating composition, a coating film and an article comprising the biocompatible material.
人工材料を生体成分と接触させると、タンパク質や血小板などが表面に付着し、材料の性能低下や生体反応への悪影響等の問題が生じるおそれがある。そのため、生体成分と接触させる用途に用いられる人工材料には表面の生体適合性が強く求められる。 When an artificial material is brought into contact with a biological component, proteins, platelets, and the like adhere to the surface, which may cause problems such as deterioration in material performance and adverse effects on biological reactions. Therefore, surface biocompatibility is strongly required for an artificial material used for contact with a biological component.
非特許文献1には、クロロトリフルオロエチレンとN−ビニルピロリドンとの共重合体及びポリビニルピロリドンからなるフッ素化両親媒性ブロック共重合体が良好な生体適合性を示すことが記載されている。 Non-Patent Document 1 describes that a copolymer of chlorotrifluoroethylene and N-vinylpyrrolidone and a fluorinated amphiphilic block copolymer composed of polyvinylpyrrolidone exhibit good biocompatibility.
特許文献1には、フッ素化モノマーと親水性モノマーを有する生体適合性ポリマーが記載されており、上記親水性モノマーとして、ビニルピロリドン等が例示されている。 Patent Document 1 describes a biocompatible polymer having a fluorinated monomer and a hydrophilic monomer. Examples of the hydrophilic monomer include vinyl pyrrolidone and the like.
このように、非特許文献1及び特許文献1には、生体適合性を有する人工材料として、フッ素化モノマーとビニルピロリドンとの共重合体が記載されている。これらの他、フッ素化モノマーとビニルピロリドンとの共重合体としては、次の共重合体が公知であるが、生体適合性の有無は不明である。 As described above, Non-Patent Document 1 and Patent Document 1 describe a copolymer of a fluorinated monomer and vinyl pyrrolidone as a biocompatible artificial material. In addition to these, the following copolymers are known as copolymers of fluorinated monomers and vinyl pyrrolidone, but the presence or absence of biocompatibility is unknown.
例えば、特許文献2には、フルオロオレフィン、N−ビニル−ラクタム化合物、架橋可能な官能基を有する単量体およびこれらと共重合可能な単量体がそれぞれ30〜70モル%、70〜5モル%、2〜40モル%、0〜63モル%の割合で共重合した含フッ素共重合体が記載されている。 For example, Patent Document 2 discloses that a fluoroolefin, an N-vinyl-lactam compound, a monomer having a crosslinkable functional group, and a monomer copolymerizable therewith are 30 to 70 mol% and 70 to 5 mol, respectively. %, 2 to 40 mol%, and a fluorine-containing copolymer copolymerized at a ratio of 0 to 63 mol%.
非特許文献2には、クロロトリフルオロエチレンとN−ビニルピロリドンとの共重合体が記載されている。 Non-Patent Document 2 describes a copolymer of chlorotrifluoroethylene and N-vinylpyrrolidone.
本発明は、改善された生体適合性を有する新規な生体適合性材料、コーティング膜及び物品を提供することを目的とする。 An object of the present invention is to provide a novel biocompatible material, coating film and article having improved biocompatibility.
より詳細には、本発明は、タンパク質、血液成分、細胞又は細菌が付着しにくい生体適合性材料、コーティング膜及び物品を提供することを目的とする。 More specifically, an object of the present invention is to provide a biocompatible material, a coating film, and an article that hardly adhere to proteins, blood components, cells, or bacteria.
更に、本発明は、生体適合性を有するコーティング膜を形成することができるコーティング組成物を提供することも目的とする。 Furthermore, another object of the present invention is to provide a coating composition that can form a biocompatible coating film.
本発明者らは、フルオロオレフィン単位及びアミド結合を有する重合性ビニル化合物単位を極めて限定された量で含むフルオロポリマーが、優れた生体適合性を示すことを見出し、本発明に到達した。 The present inventors have found that a fluoropolymer containing a very limited amount of a polymerizable vinyl compound unit having a fluoroolefin unit and an amide bond exhibits excellent biocompatibility, and has reached the present invention.
すなわち本発明は、フルオロポリマーからなる生体適合性材料であって、上記フルオロポリマーは、フルオロオレフィンとアミド結合を有する重合性ビニル化合物との共重合体であり、フルオロオレフィン単位が65〜5モル%であり、アミド結合を有する重合性ビニル化合物単位が35〜95モル%であることを特徴とする生体適合性材料である。 That is, the present invention is a biocompatible material comprising a fluoropolymer, wherein the fluoropolymer is a copolymer of a fluoroolefin and a polymerizable vinyl compound having an amide bond, and the fluoroolefin unit is 65 to 5 mol%. The biocompatible material is characterized in that the polymerizable vinyl compound unit having an amide bond is 35 to 95 mol%.
上記フルオロオレフィンは、テトラフルオロエチレン及びヘキサフルオロプロピレンからなる群より選択される少なくとも1種であることが好ましい。 The fluoroolefin is preferably at least one selected from the group consisting of tetrafluoroethylene and hexafluoropropylene.
本発明は、上述の生体適合性材料及び有機溶剤からなることを特徴とするコーティング組成物でもある。 The present invention also provides a coating composition comprising the above-described biocompatible material and an organic solvent.
本発明は、上述の生体適合性材料からなることを特徴とする物品でもある。 The present invention is also an article comprising the above-described biocompatible material.
本発明は、上述の生体適合性材料を成形して得られることを特徴とする物品でもある。 The present invention is also an article obtained by molding the above-described biocompatible material.
本発明は、上述の生体適合性材料、又は、上述のコーティング組成物を塗布して得られることを特徴とするコーティング膜でもある。 The present invention is also a coating film obtained by applying the above-described biocompatible material or the above-described coating composition.
本発明は、上述の生体適合性材料、又は、上述のコーティング組成物を塗布して得られるコーティング膜を備えることを特徴とする物品でもある。 This invention is also an article | item characterized by providing the coating film obtained by apply | coating the above-mentioned biocompatible material or the above-mentioned coating composition.
上記物品は、医療用具又は医療用容器であることが好ましい。 The article is preferably a medical device or a medical container.
本発明は、上述の物品であって、抗血栓用、バイオ医薬用、抗菌用、細胞培養用、又は、抗タンパク吸着用に使用することを特徴とする物品でもある。 The present invention is the above-described article, which is also characterized by being used for antithrombotic, biopharmaceutical, antibacterial, cell culture, or antiprotein adsorption.
本発明は、上述の物品であって、フィルム、シート、チューブ、バッグ、シャーレ、ディッシュ、ウェル、又は、バイアル瓶であることを特徴とする物品でもある。 The present invention is the above-mentioned article, which is also an article characterized by being a film, a sheet, a tube, a bag, a petri dish, a dish, a well, or a vial.
本発明は、上述の生体適合性材料、又は、上述のコーティング組成物を塗布する工程を含むことを特徴とするコーティング方法でもある。 This invention is also a coating method characterized by including the process of apply | coating the above-mentioned biocompatible material or the above-mentioned coating composition.
本発明の生体適合性材料は、上記構成を有することから、改善された生体適合性を有しており、特に、タンパク質、血液成分、細胞又は細菌が付着しにくい。また、本発明の物品及びコーティング膜は、上記構成を有することから、生体適合性に優れており、特に、タンパク質、血液成分、細胞又は細菌が付着しにくい。 Since the biocompatible material of the present invention has the above-described configuration, it has improved biocompatibility, and in particular, proteins, blood components, cells, or bacteria are difficult to adhere thereto. In addition, since the article and the coating film of the present invention have the above-described configuration, they are excellent in biocompatibility, and in particular, proteins, blood components, cells or bacteria are difficult to adhere.
本発明のコーティング組成物は、物品に生体適合性を与えるコーティング膜を形成することができる。
本発明のコーティング方法は、物品に生体適合性を与えるコーティング膜を形成することができる。The coating composition of the present invention can form a coating film that imparts biocompatibility to an article.
The coating method of the present invention can form a coating film that imparts biocompatibility to an article.
以下、本発明を具体的に説明する。 Hereinafter, the present invention will be specifically described.
本発明の生体適合性材料は、フルオロポリマーからなり、上記フルオロポリマーがフルオロオレフィンとアミド結合を有する重合性ビニル化合物との共重合体であって、上記共重合体が65〜5モル%のフルオロオレフィン単位、及び、35〜95モル%のアミド結合を有する重合性ビニル化合物単位を含むことを特徴とする。これらの特徴によって、本発明の生体適合性材料は、優れた生体適合性を有している。 The biocompatible material of the present invention comprises a fluoropolymer, and the fluoropolymer is a copolymer of a fluoroolefin and a polymerizable vinyl compound having an amide bond, and the copolymer is 65 to 5 mol% of fluoropolymer. It contains an olefin unit and a polymerizable vinyl compound unit having an amide bond of 35 to 95 mol%. Due to these characteristics, the biocompatible material of the present invention has excellent biocompatibility.
上記フルオロオレフィン単位は、上記共重合体を構成する全単量体単位に対して65〜5モル%である。一層優れた生体適合性を示すことから、上記フルオロオレフィン単位は、10モル%以上であることが好ましく、20モル%以上であることがより好ましく、30モル%以上が更に好ましく、55モル%以下であることが好ましく、45モル%以下であることがより好ましく、40モル%以下であることが更に好ましい。 The said fluoro olefin unit is 65-5 mol% with respect to all the monomer units which comprise the said copolymer. The fluoroolefin unit is preferably 10% by mole or more, more preferably 20% by mole or more, further preferably 30% by mole or more, and 55% by mole or less from the viewpoint of further excellent biocompatibility. Preferably, it is 45 mol% or less, and more preferably 40 mol% or less.
上記アミド結合を有する重合性ビニル化合物単位は、上記共重合体を構成する全単量体単位に対して35〜95モル%である。一層優れた生体適合性を示すことから、上記アミド結合を有する重合性ビニル化合物単位は、45モル%以上であることが好ましく、55モル%以上であることがより好ましく、60モル%以上であることが更に好ましく、90モル%以下であることが好ましく、80モル%以下であることがより好ましく、70モル%以下であることが更に好ましい。 The polymerizable vinyl compound unit having the amide bond is 35 to 95 mol% with respect to all monomer units constituting the copolymer. The polymerizable vinyl compound unit having an amide bond is preferably 45 mol% or more, more preferably 55 mol% or more, and more preferably 60 mol% or more because it exhibits further excellent biocompatibility. More preferably, it is 90 mol% or less, more preferably 80 mol% or less, still more preferably 70 mol% or less.
フルオロオレフィン単位が上記範囲より少なく、アミド結合を有する重合性ビニル化合物単位が多い場合は、上記共重合体が水に可溶となり、実際の使用中に共重合体が水中に溶出するため好ましくない。 When the number of fluoroolefin units is less than the above range and the number of polymerizable vinyl compound units having an amide bond is large, the copolymer is soluble in water, and the copolymer is eluted in water during actual use. .
本明細書において、フルオロオレフィン単位及びアミド結合を有する重合性ビニル化合物単位を含む共重合体を、フルオロオレフィン/アミド結合を有する重合性ビニル化合物共重合体と記載することがある。 In this specification, a copolymer containing a fluoroolefin unit and a polymerizable vinyl compound unit having an amide bond may be described as a polymerizable vinyl compound copolymer having a fluoroolefin / amide bond.
上記フルオロオレフィン/アミド結合を有する重合性ビニル化合物共重合体において、良好な生体適合性を得られることから、フルオロオレフィン単位とアミド結合を有する重合性ビニル化合物単位とのモル比(フルオロオレフィン単位/アミド結合を有する重合性ビニル化合物単位)が、1.80〜0.05であることが好ましく、0.11以上であることがより好ましく、0.25以上であることが更に好ましく、0.43以上であることがより更に好ましく、1.00以下であることがより好ましく、0.82以下であることが更に好ましく、0.67以下であることがより更に好ましい。 In the above-mentioned polymerizable vinyl compound copolymer having a fluoroolefin / amide bond, good biocompatibility can be obtained, so that the molar ratio of the fluoroolefin unit to the polymerizable vinyl compound unit having an amide bond (fluoroolefin unit / The polymerizable vinyl compound unit having an amide bond is preferably 1.80 to 0.05, more preferably 0.11 or more, further preferably 0.25 or more, 0.43 More preferably, it is more preferably 1.00 or less, still more preferably 0.82 or less, and still more preferably 0.67 or less.
上記フルオロオレフィンとしては、テトラフルオロエチレン(TFE)、ヘキサフルオロプロピレン(HFP)、クロロトリフルオロエチレン(CTFE)、フッ化ビニリデン、トリフルオロエチレン、モノフルオロエチレン、フルオロアルキルビニルエーテル、フルオロアルキルエチレン、トリフルオロプロピレン、ペンタフルオロプロピレン、トリフルオロブテン、テトラフルオロイソブテン、ヘキサフルオロイソブテン、トリフルオロスチレン、及び、一般式:CH2=CFRf(式中、Rfは炭素数1〜12の直鎖又は分岐したフルオロアルキル基)で表されるフルオロオレフィンからなる群より選択される少なくとも1種であることが好ましく、TFE、CTFE、フッ化ビニリデン及びHFPからなる群より選択される少なくとも1種であることがより好ましく、耐熱性及び耐薬品性により一層優れ、タンパク質、血液成分、細胞又は細菌がより一層付着しにくいことから、TFE及びHFPからなる群より選択される少なくとも1種であることが更に好ましい。
上記耐熱性は、次の方法により評価する。熱重量分析装置を用いて、上記フルオロポリマーを空気雰囲気下、10℃/minで600℃まで昇温する。一定重量部と重量減少部からそれぞれ接線を引き、交点を熱分解温度とする。
上記耐薬品性は、次の方法による重量減少率で評価する。上記重量減少率は、次の計算式により算出する値である。
重量減少率=100―(次亜塩素酸ナトリウム(NaClO)水溶液に浸漬した後のフルオロポリマーの重量)/(NaClO水溶液に浸漬させる前のフルオロポリマーの重量)×100
NaClO水溶液に浸漬した後の重量は、フルオロポリマー(サンプル)を、5000ppmのNaClOを含む水溶液(pH13となる様に水酸化ナトリウムを添加して調製する)に、20℃で168時間浸漬させた後、フルオロポリマーを回収し、60℃で15時間乾燥して得られるフルオロポリマーの重量である。
なお、サンプルは13質量%のフルオロポリマーを含むポリマー溶液から、直径約58mmのシャーレ上にキャスト成膜したフィルムを使用する。Examples of the fluoroolefin include tetrafluoroethylene (TFE), hexafluoropropylene (HFP), chlorotrifluoroethylene (CTFE), vinylidene fluoride, trifluoroethylene, monofluoroethylene, fluoroalkyl vinyl ether, fluoroalkylethylene, and trifluoro. Propylene, pentafluoropropylene, trifluorobutene, tetrafluoroisobutene, hexafluoroisobutene, trifluorostyrene, and general formula: CH 2 ═CFRf (wherein Rf is a linear or branched fluoroalkyl having 1 to 12 carbon atoms) Group) is preferably at least one selected from the group consisting of fluoroolefins and less selected from the group consisting of TFE, CTFE, vinylidene fluoride and HFP. Is more preferably one type, and is more excellent in heat resistance and chemical resistance, and is more difficult to adhere to proteins, blood components, cells or bacteria, so at least one selected from the group consisting of TFE and HFP More preferably.
The heat resistance is evaluated by the following method. Using a thermogravimetric analyzer, the fluoropolymer is heated to 600 ° C. at 10 ° C./min in an air atmosphere. A tangent line is drawn from each of the constant weight part and the weight reduced part, and the intersection is defined as the thermal decomposition temperature.
The chemical resistance is evaluated by the weight loss rate according to the following method. The weight reduction rate is a value calculated by the following calculation formula.
Weight reduction rate = 100− (weight of fluoropolymer after being immersed in sodium hypochlorite (NaClO) aqueous solution) / (weight of fluoropolymer before being immersed in NaClO aqueous solution) × 100
The weight of the fluoropolymer (sample) after immersion in an aqueous NaClO solution was obtained by immersing the fluoropolymer (sample) in an aqueous solution containing 5000 ppm of NaClO (prepared by adding sodium hydroxide so as to have a pH of 13) at 20 ° C. for 168 hours. The weight of the fluoropolymer obtained by recovering the fluoropolymer and drying at 60 ° C. for 15 hours.
As a sample, a film formed by casting a polymer solution containing 13% by mass of a fluoropolymer on a petri dish having a diameter of about 58 mm is used.
上記重合性ビニル化合物は、アミド結合を有しており、アミド結合に加えて重合性ビニル基を有していることが好ましい。上記アミド結合は、カルボニル基と窒素原子の間の結合をいう。
上記重合性ビニル基としては、ビニル基、アリル基、ビニルエーテル基、ビニルエステル基、アクリル基等が挙げられる。The polymerizable vinyl compound has an amide bond, and preferably has a polymerizable vinyl group in addition to the amide bond. The amide bond refers to a bond between a carbonyl group and a nitrogen atom.
Examples of the polymerizable vinyl group include a vinyl group, an allyl group, a vinyl ether group, a vinyl ester group, and an acrylic group.
上記アミド結合を有する重合性ビニル化合物としては、N−ビニル−β−プロピオラクタム、N−ビニル−2−ピロリドン、N−ビニル−γ−バレロラクタム、N−ビニル−2−ピペリドン、N−ビニル−ヘプトラクタムなどのN−ビニルラクタム化合物、N−ビニルホルムアミド、N−メチル−N−ビニルアセトアミドなどの非環状のN−ビニルアミド化合物、N−アリル−N−メチルホルムアミド、アリル尿素などの非環状のN−アリルアミド化合物、1−(2−プロペニル)−2−ピロリドンなどのN−アリルラクタム化合物、(メタ)アクリルアミド、N,N−ジメチルアクリルアミド、N−イソプロピルアクリルアミド等のアクリルアミド化合物が挙げられる。 Examples of the polymerizable vinyl compound having an amide bond include N-vinyl-β-propiolactam, N-vinyl-2-pyrrolidone, N-vinyl-γ-valerolactam, N-vinyl-2-piperidone, and N-vinyl. -N-vinyl lactam compounds such as heptolactam, acyclic N-vinylamide compounds such as N-vinylformamide and N-methyl-N-vinylacetamide, acyclic N such as N-allyl-N-methylformamide and allylurea -Allylamide compounds, N-allyl lactam compounds such as 1- (2-propenyl) -2-pyrrolidone, and acrylamide compounds such as (meth) acrylamide, N, N-dimethylacrylamide and N-isopropylacrylamide.
上記アミド結合を有する重合性ビニル化合物としては、また、
なかでも、N−ビニルラクタム化合物又は非環状のN−ビニルアミド化合物が好ましく、N−ビニル−β−プロピオラクタム、N−ビニル−2−ピロリドン、N−ビニル−γ−バレロラクタム、N−ビニル−2−ピペリドン、及び、N−ビニル−ヘプトラクタムからなる群より選択される少なくとも1種がより好ましく、N−ビニル−2−ピロリドン、及び、N−ビニル−2−ピペリドンからなる群より選択される少なくとも1種が更に好ましく、N−ビニル−2−ピロリドンが特に好ましい。 Among these, N-vinyl lactam compounds or acyclic N-vinyl amide compounds are preferable, and N-vinyl-β-propiolactam, N-vinyl-2-pyrrolidone, N-vinyl-γ-valerolactam, N-vinyl- More preferred is at least one selected from the group consisting of 2-piperidone and N-vinyl-heptlactam, and at least selected from the group consisting of N-vinyl-2-pyrrolidone and N-vinyl-2-piperidone. One is more preferred, and N-vinyl-2-pyrrolidone is particularly preferred.
上記フルオロオレフィン/アミド結合を有する重合性ビニル化合物共重合体は、本発明の効果を損なわない範囲で、フルオロオレフィン単位及びアミド結合を有する重合性ビニル化合物単位以外の他の単量体単位を有していてもよい。他の単量体単位としては、ビニルエステルモノマー単位、ビニルエーテルモノマー単位、ポリエチレングリコールを側鎖に有する(メタ)アクリルモノマー単位、ポリエチレングリコールを側鎖に有するビニルモノマー単位、長鎖炭化水素基を有する(メタ)アクリルモノマー単位、長鎖炭化水素基を有するビニルモノマー単位等が挙げられる。他の単量体単位の合計は、0〜50モル%であってもよく、0〜40モル%であることが好ましく、0〜30モル%であることがより好ましく、0〜20モル%であることが更に好ましく、0〜15モル%であることがより更に好ましく、0〜10モル%であることが特に好ましく、0〜5モル%であることが最も好ましい。 The polymerizable vinyl compound copolymer having a fluoroolefin / amide bond has a monomer unit other than the fluoroolefin unit and the polymerizable vinyl compound unit having an amide bond as long as the effects of the present invention are not impaired. You may do it. Other monomer units include vinyl ester monomer units, vinyl ether monomer units, (meth) acrylic monomer units having polyethylene glycol in the side chain, vinyl monomer units having polyethylene glycol in the side chain, and long-chain hydrocarbon groups. (Meth) acryl monomer units, vinyl monomer units having a long-chain hydrocarbon group, and the like. The total of other monomer units may be 0 to 50 mol%, preferably 0 to 40 mol%, more preferably 0 to 30 mol%, and 0 to 20 mol%. More preferably, it is more preferably 0 to 15 mol%, particularly preferably 0 to 10 mol%, and most preferably 0 to 5 mol%.
上記フルオロオレフィン/アミド結合を有する重合性ビニル化合物共重合体は、実質的にフルオロオレフィン単位及びアミド結合を有する重合性ビニル化合物単位のみからなることが好ましい。 The polymerizable vinyl compound copolymer having a fluoroolefin / amide bond preferably consists essentially of a polymerizable vinyl compound unit having a fluoroolefin unit and an amide bond.
上記フルオロオレフィン/アミド結合を有する重合性ビニル化合物共重合体は、重量平均分子量が10000以上であることが好ましい。より好ましくは、15000〜500000であり、更に好ましくは、20000〜300000である。上記重量平均分子量は、ゲル浸透クロマトグラフィー(GPC)により求めることができる。 The polymerizable vinyl compound copolymer having a fluoroolefin / amide bond preferably has a weight average molecular weight of 10,000 or more. More preferably, it is 15000-500000, More preferably, it is 20000-300000. The weight average molecular weight can be determined by gel permeation chromatography (GPC).
上記フルオロオレフィン/アミド結合を有する重合性ビニル化合物共重合体は、ラジカル重合によって製造できる。製造プロセスの種類や媒体の種類・有無、重合反応系内の均一性等に関して特に限定されることはないが、例えば、溶液重合、乳化重合、ソープフリー重合、懸濁重合、沈殿重合、分散重合、塊状重合などにより製造できる。 The polymerizable vinyl compound copolymer having a fluoroolefin / amide bond can be produced by radical polymerization. There are no particular limitations regarding the type of production process, the type / presence of the medium, uniformity within the polymerization reaction system, etc., for example, solution polymerization, emulsion polymerization, soap-free polymerization, suspension polymerization, precipitation polymerization, dispersion polymerization Or by bulk polymerization.
上記生体適合性材料からは生体適合性に優れた物品を製造できる。また、上記生体適合性材料は、物品の表面に生体適合性の膜を形成することができる。上記生体適合性材料は、コーティング膜であることが好適な態様の一つである。上記コーティング膜とは、上記生体適合性材料又は上記生体適合性材料からなるコーティング組成物を塗布することにより得られる膜をいう。上記コーティング膜の製膜方法としては、スピンコート法、ドロップキャスト法、ディップニップ法、スプレーコート法、刷毛塗り法、浸漬法、静電塗装法、インクジェットプリント法等が挙げられる。中でも、簡便性の点で、スピンコート法、ドロップキャスト法、浸漬法が好ましい。 An article having excellent biocompatibility can be produced from the biocompatible material. The biocompatible material can form a biocompatible film on the surface of the article. In one preferred embodiment, the biocompatible material is a coating film. The said coating film means the film | membrane obtained by apply | coating the coating composition which consists of the said biocompatible material or the said biocompatible material. Examples of the method for forming the coating film include spin coating, drop casting, dip nip, spray coating, brush coating, dipping, electrostatic coating, and inkjet printing. Of these, spin coating, drop casting, and dipping are preferred from the standpoint of simplicity.
上記コーティング膜の膜厚は0.1〜50μmであることが好ましく、0.5〜30μmであることがより好ましく、1.0〜20μmであることが更に好ましい。 The thickness of the coating film is preferably 0.1 to 50 μm, more preferably 0.5 to 30 μm, and still more preferably 1.0 to 20 μm.
上記生体適合性材料及び有機溶剤からなることを特徴とするコーティング組成物も本発明の一つである。上記コーティング膜は、上記コーティング組成物を塗布することにより得られることが好ましい。 A coating composition comprising the biocompatible material and an organic solvent is also one aspect of the present invention. The coating film is preferably obtained by applying the coating composition.
上記有機溶剤としては、メタノール、エタノール、2−プロパノール、2−ブタノール、1−ブタノール、1−ヘキサノール、アセトン、テトラヒドロフラン、メチルエチルケトン、ジメチルアセトアミド、ジメチルホルムアミド等が使用できる。なかでも、透明で均一なコーティング膜が容易に得られる点で、2−ブタノール、1−ブタノール、1−ヘキサノール、テトラヒドロフランが好ましい。また、上記生体適合性材料の溶解性の観点からは、メタノール、エタノール、2−プロパノール、テトラヒドロフラン、ジメチルアセトアミド、ジメチルホルムアミドが好ましい。 As the organic solvent, methanol, ethanol, 2-propanol, 2-butanol, 1-butanol, 1-hexanol, acetone, tetrahydrofuran, methyl ethyl ketone, dimethylacetamide, dimethylformamide and the like can be used. Of these, 2-butanol, 1-butanol, 1-hexanol, and tetrahydrofuran are preferable in that a transparent and uniform coating film can be easily obtained. From the viewpoint of solubility of the biocompatible material, methanol, ethanol, 2-propanol, tetrahydrofuran, dimethylacetamide, and dimethylformamide are preferable.
上記生体適合性材料は、優れた生体適合性を有することから、医療用具又は医療用容器を形成するための材料として好適に使用できる。また、上記生体適合性材料は、タンパク質、血液成分、細胞又は細菌が付着しにくいことから、タンパク質、血液成分、細胞又は細菌の付着を避けることが要求される種々の物品に適用できる。 Since the said biocompatible material has the outstanding biocompatibility, it can be used conveniently as a material for forming a medical device or a medical container. The biocompatible material can be applied to various articles that are required to avoid adhesion of proteins, blood components, cells, or bacteria because proteins, blood components, cells, or bacteria are difficult to adhere.
上記タンパク質としては、血漿タンパク質、後述するバイオ医薬等を挙げることができる。上記血漿タンパク質としては、アルブミン、グロブリン、フィブリノーゲン等が挙げられる。上記血液成分としては、血小板等を挙げることができる。 Examples of the protein include plasma proteins and biopharmaceuticals described below. Examples of the plasma protein include albumin, globulin, and fibrinogen. Examples of the blood component include platelets.
上記物品は、上記生体適合性材料を公知の成形方法により成形して得られたものであってもよいし、上記生体適合性材料又は上記生体適合性材料からなるコーティング組成物を、医療用具又は医療用容器等の物品に塗布することにより得られたものであってもよい。また、上記物品は、上記コーティング膜を備えるものであってもよく、物品の表面に上記コーティング膜を備えるものであってもよい。 The article may be obtained by molding the biocompatible material by a known molding method, or the biocompatible material or the coating composition comprising the biocompatible material may be used as a medical device or What was obtained by apply | coating to articles | goods, such as a medical container, may be used. In addition, the article may be provided with the coating film, or may be provided with the coating film on the surface of the article.
上記生体適合性材料の成形方法及び塗布方法は特に限定されず、スピンコート法、ドロップキャスト法、ディップニップ法、スプレーコート法、刷毛塗り法、浸漬法、インクジェットプリント法、静電塗装法、圧縮成形法、押出成形法、カレンダー成形法、トランスファー成形法、射出成形法、ロト成形法、ロトライニング成形法、熱誘起相分離法、非溶媒誘起相分離法等が採用できる。 The molding method and coating method of the biocompatible material are not particularly limited, and spin coating method, drop casting method, dip nip method, spray coating method, brush coating method, dipping method, inkjet printing method, electrostatic coating method, compression method A molding method, an extrusion molding method, a calender molding method, a transfer molding method, an injection molding method, a loto molding method, a lotining molding method, a thermally induced phase separation method, a non-solvent induced phase separation method, and the like can be employed.
上記生体適合性材料からなることを特徴とする物品、上記生体適合性材料を成形して得られることを特徴とする物品、上記生体適合性材料又は上記コーティング組成物を塗布して得られることを特徴とするコーティング膜、及び、上記生体適合性材料又は上記コーティング組成物を塗布して得られるコーティング膜を備えることを特徴とする物品は、いずれも、生体適合性に優れている。上記物品は、医療用具又は医療用容器として好適に利用できる。 An article comprising the biocompatible material, an article obtained by molding the biocompatible material, and obtained by applying the biocompatible material or the coating composition. Any of the articles comprising the characteristic coating film and the coating film obtained by applying the biocompatible material or the coating composition is excellent in biocompatibility. The article can be suitably used as a medical device or a medical container.
上記生体適合性材料又は上記コーティング組成物を塗布する工程を含むことを特徴とするコーティング方法も本発明の一つである。上記コーティング方法において、上記生体適合性材料又は上記コーティング組成物を物品の表面に塗布することが好ましい。上記コーティング方法によって、物品の表面に生体適合性に優れたコーティング膜を付与することができる。 The coating method characterized by including the step of applying the biocompatible material or the coating composition is also one aspect of the present invention. In the coating method, the biocompatible material or the coating composition is preferably applied to the surface of an article. By the coating method, a coating film having excellent biocompatibility can be imparted to the surface of the article.
上記物品の形状は特に限定されず、フィルム、シート、チューブ、バッグ、シャーレ、ディッシュ、ウェル、又は、バイアル瓶であってよい。 The shape of the article is not particularly limited, and may be a film, a sheet, a tube, a bag, a petri dish, a dish, a well, or a vial.
上記物品は、抗血栓用、バイオ医薬用、抗菌用、細胞培養用、又は、抗タンパク吸着用に好適に使用できる。上記物品であって、抗血栓用、バイオ医薬用、抗菌用、細胞培養用、又は、抗タンパク吸着用に使用することを特徴とする物品も本発明の一つである。 The article can be suitably used for antithrombotic, biopharmaceutical, antibacterial, cell culture, or antiprotein adsorption. The above-mentioned article, which is used for antithrombotic, biopharmaceutical, antibacterial, cell culture, or antiprotein adsorption, is also one aspect of the present invention.
上記抗血栓用物品としては、バイアル瓶、人工血管、ステント、カテーテル、人工心臓、人工肺、人工心弁、血液保存バッグ等が好ましい。 As the antithrombotic article, a vial, an artificial blood vessel, a stent, a catheter, an artificial heart, an artificial lung, an artificial heart valve, a blood storage bag, and the like are preferable.
上記バイオ医薬用物品としては、バイオ医薬用シート、バイオ医薬用フィルム、バイオ医薬用バイアル瓶、バイオ医薬用シャーレ、バイオ医薬用フラスコ等が挙げられる。 Examples of the biopharmaceutical article include a biopharmaceutical sheet, a biopharmaceutical film, a biopharmaceutical vial, a biopharmaceutical petri dish, and a biopharmaceutical flask.
バイオ医薬を保管するための器具やバイオ医薬を使用するための器具にバイオ医薬が吸着しやすいと、バイオ医薬を正確に定量できなかったり、正確な分析が困難になったりする。また、バイオ医薬は高価であるため、経済的損失も大きい。バイオ医薬用バッグ、バイオ医薬用シート、バイオ医薬用フィルム、バイオ医薬用バイアル瓶、バイオ医薬用シャーレ、又は、バイオ医薬用フラスコが、上述の生体適合性材料からなるものであると、バイオ医薬が吸着しにくく、バイオ医薬を高い回収率で回収することができる。 If the biopharmaceutical is easily adsorbed to an instrument for storing the biopharmaceutical or an instrument for using the biopharmaceutical, the biopharmaceutical cannot be accurately quantified or accurate analysis becomes difficult. In addition, since biopharmaceuticals are expensive, there is a great economic loss. When the biopharmaceutical bag, the biopharmaceutical sheet, the biopharmaceutical film, the biopharmaceutical vial, the biopharmaceutical petri dish, or the biopharmaceutical flask is made of the above-described biocompatible material, It is difficult to adsorb and biopharmaceuticals can be recovered at a high recovery rate.
上記バイオ医薬としては、タンパク質医薬品、遺伝子組み換えウイルス、細胞性治療薬、核酸医薬品等が挙げられる。 Examples of the biopharmaceutical include protein drugs, genetically modified viruses, cellular therapeutic drugs, and nucleic acid drugs.
上記タンパク質医薬品としては、(1)酵素類のタンパク質:アルテラーゼ、モンテブラーゼ、イミグルセラーゼ、ベラグルセラーゼ アルファ、アガルシダーゼ アルファ、アガルシダーゼ ベータ、ラロニダーゼ、アルグルコシダーゼ アルファ、イデュルスルファーゼ、ガルスルファーゼ、ラスブリカーゼ、ドルナーゼ アルファ、(2)血液凝固線溶系因子類のタンパク質:オクトコグ アルファ、ルリオクトコグ アルファ、エプタコグ アルファ(活性型)、ノナコグアルファ、ツロクトコグ アルファ、エフトレノナコグ アルファ、トロンボモデュリン アルファ、(3)血清タンパク質類:人血清アルブミン、(4)ホルモン類のタンパク質:ヒトインスリン、インスリン リスプロ、インスリン アスパルト、インスリン グラルギン、インスリン デテミル、インスリン グルリジン、インスリン デグルデク、インスリン デグルデク及びインスリン アスパルト、ソマトロピン、ペグビソマント、メカセルミン、カルペリチド、グルカゴン、ホリトロピン アルファ、フォリトロピン ベータ、リラグルチド、テリパラチド、メトレレプチン、(5)ワクチン類のタンパク質:組換え沈降B型肝炎ワクチン(酵母由来)、乾燥細胞培養不活化A型肝炎ワクチン、組換え沈降2価ヒトパピローマウイルス様粒子ワクチン(イラクサギンウワバ細胞由来)、組換え沈降4価ヒトパピローマウイルス様粒ワクチン(酵母由来)、(6)インターフェロン類のタンパク質:インターフェロン アルファ(NAMALWA)、インターフェロン アルファ−2b、インターフェロン アルファ(BALL−1)、インターフェロン アルファコン−1、インターフェロン ベータ、インターフェロン ベータ−1a、インターフェロン ベータ−1b、インターフェロン ガンマ−1a、ペグインターフェロン アルファ−2a、ペグインターフェロン アルファ−2b、(7)エリスロポエチン類のタンパク質:エポエチン アルファ、エポエチン ベータ、ダルベポエチン アルファ、エポエチン ベータ ペゴル、エポエチン カッパ、(8)サイトカイン類のタンパク質:フィルグラスチム、ペグフィルグラスチム、レノグラスチム、ナルトグラスチム、セルモロイキン、テセロイキン、トラフェルミン、(9)抗体類のタンパク質:ムロモナブ−CD3、トラスツズマブ、リツキシマブ、パリビズマブ、インフリキシマブ、バシリキシマブ、トシリズマブ、ゲムツズマブ オゾガマイシン、ベバシズマブ、イブリツモマブ チウキセタン、アダリムマブ、セツキシマブ、ラニビズマブ、オマリズマブ、エクリズマブ、パニツムマブ、ウステキヌマブ、ゴリムマブ、カナキヌマブ、デノスマブ、モガムリズマブ、セルトリズマブ ペゴル、オファツムマブ、ペルツズマブ、トラスツズマブ エムタンシン、ブレンツキシマブ ベドチン、ナタリズマブ、ニボルマブ、アレムツズマブ、(10)融合タンパク質類:エタネルセプト、アバタセプト、ロミプロスチム、アフリベルセプト等が挙げられる。 The above protein drugs include: (1) Enzymes proteins: Arterase, Montebrase, Imiglucerase, Veraglucerase alpha, Agarcidase alpha, Agarcidase beta, Laronidase, Alglucosidase alpha, Idursulfase, Galsulfase, Rasburicase, Dornase alpha, (2 ) Proteins of blood coagulation and fibrinolytic factors: Octocog alpha, Luriooctocog alpha, Eptacog alpha (active), Nonacog alpha, Turoctocog alpha, Eftrenonacog alpha, thrombomodulin alpha, (3) Serum proteins: Human serum albumin, (4) Hormonal proteins: human insulin, insulin lispro, insulin aspart, insulin glal Gin, Insulin detemir, Insulin glulysine, Insulin degludec, Insulin degludec and Insulin aspart, Somatropin, Pegvisomant, Mecasermine, Carperitide, Glucagon, Follitropin alpha, Follitropin beta, Liraglutide, Teriparatide, Metreleptin, (5) Vaccine protein recombinant: Precipitated hepatitis B vaccine (derived from yeast), dry cell culture inactivated hepatitis A vaccine, recombinant precipitated bivalent human papilloma virus-like particle vaccine (derived from nettle wabas cell), recombinant precipitated tetravalent human papilloma virus-like granule vaccine (yeast Origin), (6) Interferon proteins: interferon alpha (NAMALWA), interferon alpha-2b, interferon Alpha (BALL-1), interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, interferon gamma-1a, peginterferon alpha-2a, peginterferon alpha-2b, (7) proteins of erythropoietins : Epoetin alfa, epoetin beta, darbepoetin alfa, epoetin beta pegol, epoetin kappa, (8) proteins of cytokines: filgrastim, pegfilgrastim, lenograstim, nartograstim, sermoleukin, teseleukin, trafermin, (9 ) Proteins of antibodies: muromonab-CD3, trastuzumab, rituximab, palivizumab, infliximab Basiliximab, tocilizumab, gemtuzumab ozogamicin, bevacizumab, ibritumomab tiuxetan, adalimumab, cetuximab, ranibizumab, omalizumab, eculizumab, panitumumab, Usutekinumabu, golimumab, Kanakinumabu, denosumab, mogamulizumab, certolizumab pegol, ofatumumab, pertuzumab, trastuzumab Emutanshin, brentuximab Bedochin, natalizumab , Nivolumab, alemtuzumab, (10) fusion proteins: etanercept, abatacept, romiplostim, aflibercept and the like.
また、核酸医薬品としては、アンチセンス、siRNA、デコイ核酸、核酸アプタマー、リボザイム、miRNAアンチセンス、miRNAmimic、CpGオリゴデオキシヌクレオチドが挙げられる。 Examples of nucleic acid pharmaceuticals include antisense, siRNA, decoy nucleic acid, nucleic acid aptamer, ribozyme, miRNA antisense, miRNAmimic, and CpG oligodeoxynucleotide.
上記抗菌用物品としては、コンタクトレンズ、トイレタリー用品、キッチン水回り器具、エアコン、食品工場設備、下水処理場設備、排水管等が挙げられる。 Examples of the antibacterial article include contact lenses, toiletries, kitchen watering equipment, air conditioners, food factory equipment, sewage treatment plant equipment, and drain pipes.
上記細胞培養用物品としては、細胞培養用バッグ、細胞培養用シート、細胞培養用フィルム、細胞培養用バイアル瓶、細胞培養用シャーレ、細胞培養用フラスコ等が挙げられる。 Examples of the cell culture article include a cell culture bag, a cell culture sheet, a cell culture film, a cell culture vial, a cell culture petri dish, and a cell culture flask.
上記細胞培養用物品としては、また、胚様体形成用培養容器も挙げられる。上記胚様体形成用培養容器は、2個以上のウェルを有することが好ましい。各ウェルの形状は特に限定されないが、垂直方向における断面が略U字形状の底部、及び、略円形の開口部を有することが好ましい。更に、上記底部内面の曲率半径(R’)が、1.0mm以上、3.5mm以下であることが好ましく、3.0mm以下とすることがより好ましい。上記開口部の直径は4.0〜11.0mmとすることが好ましい。各ウェルの容量は80〜500μLとすることができる。上記胚様体形成用培養容器は、少なくともウェルの内面が上記生体適合性材料からなるものであることが好ましい。 Examples of the cell culture article also include a culture container for embryoid body formation. The culture container for embryoid body formation preferably has two or more wells. Although the shape of each well is not particularly limited, it is preferable that the cross section in the vertical direction has a substantially U-shaped bottom portion and a substantially circular opening. Furthermore, the curvature radius (R ′) of the inner surface of the bottom is preferably 1.0 mm or more and 3.5 mm or less, and more preferably 3.0 mm or less. The diameter of the opening is preferably 4.0 to 11.0 mm. The volume of each well can be 80-500 μL. In the embryoid body-forming culture container, at least the inner surface of the well is preferably made of the biocompatible material.
細胞を培養するために使用する器具に細胞が付着しやすいと、培養した細胞の回収率が低下したり、細胞が増殖している形状のまま回収できなかったり、細胞の性質が変化してしまったりする。細胞培養用バッグ、細胞培養用シート、細胞培養用フィルム、細胞培養用バイアル瓶、細胞培養用シャーレ又は細胞培養用フラスコが、上述の生体適合性材料からなるものであると、細胞が付着しにくく、培養により得られた細胞を高い回収率で、かつ細胞の形状や性質を好ましい状態で回収することができる。 If cells tend to adhere to the equipment used to culture the cells, the recovery rate of the cultured cells will decrease, the cells will not be recovered in their proliferated form, or the properties of the cells will change. I'll be relaxed. When the cell culture bag, the cell culture sheet, the cell culture film, the cell culture vial, the cell culture petri dish or the cell culture flask are made of the biocompatible material described above, the cells are less likely to adhere. The cells obtained by culturing can be recovered at a high recovery rate and in a preferable state of the shape and properties of the cells.
上記細胞としては、造血幹細胞、神経幹細胞、間葉系肝細胞、中胚葉系幹細胞、肝幹細胞、膵幹細胞、胚性幹細胞等の幹細胞や、幹細胞を目的の細胞に分化させた細胞、あるいは免疫系細胞、血球系細胞、神経細胞、血管内皮細胞、繊維芽細胞、上皮細胞、角化細胞、角膜細胞、骨芽細胞、軟骨細胞、脂肪細胞、表皮細胞、肝細胞、膵β細胞、心筋細胞、骨髄細胞、羊膜細胞、臍帯血細胞などの生体由来の細胞、あるいはNIH3T3(エヌアイエイチスリーティースリー)細胞、3T3−L1(スリーティースリーエルワン)細胞、3T3−E1(スリーティースリーイーワン)細胞、HeLa(ヒーラ)細胞、PC−12(ピーシーツェルブ)細胞、P19(ピーナインティーン)細胞、CHO(チャイニーズハムスター卵母)細胞、COS(シーオーエス)細胞、HEK(エッチイーケー)細胞、Hep−G2(ヘップジーツー)細胞、L929(エルナインツーナイン)細胞、C2C12(シーツーシーツェルブ)細胞、Daudi(ダウディ)細胞、Jurkat(ジャーカット)細胞、KG−1a(ケージーワンエー)細胞、CTLL−2(シーティーエルエルツー)細胞、NS−1(エヌエスワン)細胞、MOLT−4(エムオーエルティーフォー)細胞、HUT78(エッチユーティーセブンティエイト)細胞、MT−4(エムティーフォー)細胞などの株化細胞、あるいは抗体産生細胞である各種ハイブリドーマ細胞株、あるいはこれら細胞を遺伝子工学的に改変した細胞が挙げられる。 Examples of the cells include hematopoietic stem cells, neural stem cells, mesenchymal hepatocytes, mesodermal stem cells, hepatic stem cells, pancreatic stem cells, embryonic stem cells, and the like, cells obtained by differentiating stem cells into target cells, or the immune system Cells, blood cells, neurons, vascular endothelial cells, fibroblasts, epithelial cells, keratinocytes, corneal cells, osteoblasts, chondrocytes, adipocytes, epidermal cells, hepatocytes, pancreatic β cells, cardiomyocytes, Cells derived from living bodies such as bone marrow cells, amniotic cells, umbilical cord blood cells, NIH3T3 cells, 3T3-L1 cells, 3T3-E1 cells, HeLa ( HeLa) cells, PC-12 (PC Zelb) cells, P19 (Pineteen) cells, CHO (Chinese hamster oocytes) cells, C S (COS) cells, HEK (Heek-Ek) cells, Hep-G2 (Hepsey two) cells, L929 (El Nine to Nine) cells, C2C12 (C2C Zerub) cells, Daudi (Daudi) cells, Jurkat ( Jurkat) cells, KG-1a cells, CTLL-2 cells, NS-1 cells, MOLT-4 cells, HUT78 Eight) cells, cell lines such as MT-4 (MT4) cells, various hybridoma cell lines that are antibody-producing cells, or cells obtained by genetically modifying these cells.
特に高分子材料に付着しやすい細胞である接着性細胞を培養する場合であっても、上記細胞培養用物品であれば、培養した細胞の付着を抑制することができる。 Even in the case of culturing adherent cells, which are cells that are particularly likely to adhere to the polymer material, the above-mentioned cell culture article can suppress adhesion of the cultured cells.
上記細胞としては、胚性幹細胞(ES細胞)や人工多能性幹細胞(iPS細胞)などの胚様体(embryoid body:EB)も挙げられる。 Examples of the cells include embryoid bodies (EBs) such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).
胚様体形成は、ES細胞をはじめとする多能性幹細胞をin vitroで分化誘導する際に有効であるため、広く採用されている手法である。胚様体形成はES細胞やiPS細胞を培養容器に接着させない浮遊状態で培養することが重要であり、通常の培養容器を使用した接着培養では胚様体は形成されにくい。上記胚様体形成用培養器が、上述の生体適合性材料からなるものであると、均一で、効率よく、質の高い胚様体を形成することができる。 Embryoid body formation is a widely adopted technique because it is effective in inducing differentiation of pluripotent stem cells including ES cells in vitro. In embryoid body formation, it is important to culture ES cells and iPS cells in a floating state where they are not allowed to adhere to the culture vessel, and it is difficult to form embryoid bodies in adhesion culture using a normal culture vessel. When the embryoid body-forming incubator is made of the above-described biocompatible material, a high-quality embryoid body can be formed uniformly and efficiently.
上記抗タンパク吸着用物品としては、上述した抗血栓用物品、バイオ医薬用物品、抗菌用物品、細胞培養用物品等が挙げられる。 Examples of the anti-protein adsorbing article include the anti-thrombotic article, biopharmaceutical article, antibacterial article, and cell culture article described above.
上記生体適合性材料を上記物品に適用する工程を含むことを特徴とする、上記物品へのタンパク質、血液成分、細胞又は細菌の付着を防止する方法は、上記生体適合性材料の使用方法として好ましい。上記生体適合性材料を適用する方法は、特に限定されず、物品の少なくとも表面の一部を上記生体適合性材料で覆うことができる方法であれば特に限定されない。例えば、上記生体適合性材料又は上記生体適合性材料を含むコーティング組成物を塗布することによりコーティング膜を形成させる方法が挙げられる。 A method for preventing adhesion of proteins, blood components, cells, or bacteria to the article, comprising the step of applying the biocompatible material to the article is preferable as a method for using the biocompatible material. . The method of applying the biocompatible material is not particularly limited as long as it is a method that can cover at least a part of the surface of the article with the biocompatible material. For example, the method of forming a coating film by apply | coating the said biocompatible material or the coating composition containing the said biocompatible material is mentioned.
上記物品表面の大腸菌の増殖を阻害する方法であって、上記物品の表面に上記生体適合性材料を適用することを特徴とする方法も、上記生体適合性材料の使用方法として好ましい。上記生体適合性材料を適用する方法は、特に限定されず、物品の少なくとも表面の一部を上記生体適合性材料で覆うことができる方法であれば特に限定されない。例えば、上記生体適合性材料又は上記生体適合性材料を含むコーティング組成物を塗布することによりコーティング膜を形成させる方法が挙げられる。 A method for inhibiting the growth of E. coli on the surface of the article, wherein the biocompatible material is applied to the surface of the article, is also preferable as a method for using the biocompatible material. The method of applying the biocompatible material is not particularly limited as long as it is a method that can cover at least a part of the surface of the article with the biocompatible material. For example, the method of forming a coating film by apply | coating the said biocompatible material or the coating composition containing the said biocompatible material is mentioned.
つぎに本発明を実施例をあげて説明するが、本発明はかかる実施例のみに限定されるものではない。 Next, the present invention will be described with reference to examples, but the present invention is not limited to such examples.
実施例の各数値は以下の方法により測定した。 Each numerical value of the examples was measured by the following method.
モノマーのモル比
元素分析により測定した。The molar ratio of the monomer was measured by elemental analysis.
分子量の測定はゲル浸透クロマトグラフィー(GPC)測定により行った。 The molecular weight was measured by gel permeation chromatography (GPC) measurement.
製造例1
テトラフルオロエチレンとN−ビニルピロリドンの共重合体(1)の調製
気密検査済みの耐圧性反応容器内を十分に窒素置換した後、脱酸素処理したアセトン(752g)及びN−ビニルピロリドン(27.2g)を添加した。続いてテトラフルオロエチレン(100g)を加圧添加し、攪拌しながら混合物の内温を60℃となる様に調整した上で、t−ブチルパーオキシピバレート1.7gを加えて反応を開始した。反応開始から35分後、残存するテトラフルオロエチレンを除去し、精製、乾燥することで目的の共重合体(1)を15g得た。得られた共重合体(1)は、重量平均分子量6.4×104、分子量分布1.9、50モル%のテトラフルオロエチレン単位及び50モル%のN−ビニルピロリドン単位を含む共重合体であることが分かった。テトラフルオロエチレン単位/N−ビニルピロリドン単位のモル比は1であり、フッ素含有率は36質量%であった。Production Example 1
Preparation of Copolymer (1) of Tetrafluoroethylene and N-Vinylpyrrolidone The inside of the pressure-resistant reaction vessel that had been subjected to airtightness inspection was sufficiently purged with nitrogen, and then deoxygenated acetone (752 g) and N-vinylpyrrolidone (27. 2 g) was added. Subsequently, tetrafluoroethylene (100 g) was added under pressure, the internal temperature of the mixture was adjusted to 60 ° C. while stirring, and 1.7 g of t-butyl peroxypivalate was added to initiate the reaction. . After 35 minutes from the start of the reaction, the remaining tetrafluoroethylene was removed, purified and dried to obtain 15 g of the desired copolymer (1). The obtained copolymer (1) is a copolymer comprising a weight average molecular weight of 6.4 × 10 4 , a molecular weight distribution of 1.9, 50 mol% of tetrafluoroethylene units and 50 mol% of N-vinylpyrrolidone units. It turns out that. The molar ratio of tetrafluoroethylene unit / N-vinylpyrrolidone unit was 1, and the fluorine content was 36% by mass.
製造例2
テトラフルオロエチレンとN−ビニルピロリドンの共重合体(2)の調製
気密検査済みの耐圧性反応容器内を十分に窒素置換した後、脱酸素処理したメチルイソブチルケトン(90.3g)及びN−ビニルピロリドン(9.80g)を添加した。続いてテトラフルオロエチレンを加圧添加し、スターラーで攪拌しながら混合物の内温を60℃となる様に調整した上で、アゾビスイソブチロニトリル(0.197g)を加えて反応を開始した。反応開始から1時間後、残存するテトラフルオロエチレンを除去し、ヒドロキノン(0.132g)を添加した。次いで反応混合物を精製、乾燥させ目的の共重合体(2)を3.3g得た。得られた共重合体(2)は、重量平均分子量6.5×104、分子量分布2.0、34モル%のテトラフルオロエチレン単位及び66モル%のN−ビニルピロリドン単位を含む共重合体であった。テトラフルオロエチレン単位/N−ビニルピロリドン単位のモル比は0.52であり、フッ素含有率は24質量%であった。Production Example 2
Preparation of copolymer (2) of tetrafluoroethylene and N-vinylpyrrolidone The inside of a pressure-resistant reaction vessel that had been subjected to airtightness inspection was sufficiently purged with nitrogen, and then deoxygenated methyl isobutyl ketone (90.3 g) and N-vinyl Pyrrolidone (9.80 g) was added. Subsequently, tetrafluoroethylene was added under pressure, and while stirring with a stirrer, the internal temperature of the mixture was adjusted to 60 ° C., and azobisisobutyronitrile (0.197 g) was added to initiate the reaction. . One hour after the start of the reaction, the remaining tetrafluoroethylene was removed, and hydroquinone (0.132 g) was added. The reaction mixture was then purified and dried to obtain 3.3 g of the desired copolymer (2). The obtained copolymer (2) has a weight average molecular weight of 6.5 × 10 4 , a molecular weight distribution of 2.0, a copolymer containing 34 mol% of tetrafluoroethylene units and 66 mol% of N-vinylpyrrolidone units. Met. The molar ratio of tetrafluoroethylene unit / N-vinylpyrrolidone unit was 0.52, and the fluorine content was 24% by mass.
共重合体(1)及び(2)について表1に示す。
実施例1
共重合体(1)の0.1質量%メタノール溶液を室温でPETコーティング済みQCMチップ(円盤状:直径1.4cm)の片側反応面へスピンコートした。具体的には、上記溶液30μLをPETコーティング済みQCMチップ上に滴下し、60秒間、2000rpm回転させた。その後、室温にて3時間、ロータリー真空ポンプにて減圧乾燥し、コーティング膜(QCMチップ)を得た。得られたコーティング膜をQCM−Dに組み込み、以下の方法でコーティング膜上のタンパク質吸着試験(ウシ血清アルブミン)を評価した。実験の結果を表2〜4に示す。Example 1
A 0.1% by mass methanol solution of copolymer (1) was spin-coated at room temperature on one side reaction surface of a PET-coated QCM chip (disk shape: diameter 1.4 cm). Specifically, 30 μL of the above solution was dropped on a PET-coated QCM chip and rotated at 2000 rpm for 60 seconds. Then, it dried under reduced pressure with the rotary vacuum pump at room temperature for 3 hours, and obtained the coating film (QCM chip). The obtained coating film was incorporated into QCM-D, and the protein adsorption test (bovine serum albumin) on the coating film was evaluated by the following method. The results of the experiment are shown in Tables 2-4.
〔タンパク質吸着試験〕
上記の方法でPETコーティング済みQCMチップに重ねて共重合体(1)をコーティングしたQCMチップをQCM−Dに装着させ、23.4℃環境下のリン酸緩衝生理食塩水(PBS)中で安定化を行った。[Protein adsorption test]
The QCM chip coated with copolymer (1) on the PET-coated QCM chip by the above method is attached to QCM-D, and stable in phosphate buffered saline (PBS) at 23.4 ° C. Made.
周波数のベースラインが水平であることを確認した上、タンパク質を含むリン酸緩衝生理食塩水溶液(タンパク質の濃度0.05mg/mL)を0.5mL注入し、吸着時間30分間の周波数の変化量を測定した。タンパク質としては、ウシ血清アルブミン(BSA)またはウシ血漿フィブリノーゲン(BPF)およびウシ血清由来免疫グロブリンG(IgG)を使用した。 After confirming that the frequency baseline is horizontal, 0.5 mL of a phosphate buffered saline solution containing protein (protein concentration 0.05 mg / mL) is injected, and the amount of change in frequency over an adsorption time of 30 minutes is measured. It was measured. As proteins, bovine serum albumin (BSA) or bovine plasma fibrinogen (BPF) and bovine serum-derived immunoglobulin G (IgG) were used.
コーティング膜に吸着したタンパク質量は、実験から得られた吸着時間30分後の周波数を解析ソフトQToolsに導入されているSauerbreyの式からAreal mass[ng/cm2]の解析を行い算出した。The amount of protein adsorbed on the coating film was calculated by analyzing the real mass [ng / cm 2 ] from the Sauerbrey equation introduced in the analysis software QTools, based on the frequency after 30 minutes of adsorption time obtained from the experiment.
実施例2〜6
実施例1と同様にQCM−Dを用いて、表2〜4に記載したように、共重合体(1)または(2)について、ウシ血清アルブミン(BSA)またはウシ血漿フィブリノーゲン(BPF)およびグロブリン(IgG)の吸着を評価した。実験の結果を表2〜4に示す。Examples 2-6
Bovine serum albumin (BSA) or bovine plasma fibrinogen (BPF) and globulin for copolymers (1) or (2) as described in Tables 2-4 using QCM-D as in Example 1. Adsorption of (IgG) was evaluated. The results of the experiment are shown in Tables 2-4.
比較例1〜3(PET)
ポリエチレンテレフタレート(PET)の1.0質量%溶液(トリフルオロ酢酸、ジクロロメタンと1,1,2,2−テトラクロロエタンの混合溶剤(混合比1/4/45)に溶解させたもの)を室温でQCMチップ(円盤状:直径1.4cm)の片側反応面へスピンコートした。具体的には、上記溶液30μLをQCMチップ上に滴下し、60秒間、2000rpm回転させた。その後、50℃にて3時間以上、ロータリー真空ポンプにて減圧乾燥し、コーティング膜を得た。
得られたコーティング膜について実施例1〜6と同様にタンパク質の吸着試験を実施した。実験の結果を表2〜4に示す。Comparative Examples 1-3 (PET)
A 1.0% by mass solution of polyethylene terephthalate (PET) (dissolved in a mixed solvent of trifluoroacetic acid, dichloromethane and 1,1,2,2-tetrachloroethane (mixing ratio 1/4/45)) at room temperature A single-side reaction surface of a QCM chip (disc shape: diameter 1.4 cm) was spin coated. Specifically, 30 μL of the above solution was dropped on a QCM chip and rotated at 2000 rpm for 60 seconds. Then, it dried under reduced pressure with the rotary vacuum pump at 50 degreeC for 3 hours or more, and obtained the coating film.
The obtained coating film was subjected to the protein adsorption test in the same manner as in Examples 1-6. The results of the experiment are shown in Tables 2-4.
実施例7
共重合体(1)の0.1質量%メタノール溶液を室温でPETフィルム(1cm×1cm)上へスピンコートした。具体的には、上記溶液30μLをPETフィルム上に滴下し200rpmで10秒間回転した。その後、室温にて、ロータリー真空ポンプにて減圧乾燥し、コーティング膜を得た。さらにこのコーティングされたPETフィルムを0.5cm×0.5cmにカットしコーティング膜(PETフィルムの表面に形成されたコーティング膜)を得た。得られたコーティング膜について、以下の方法で抗血栓性(30分間)を評価した。結果を表5に示す。Example 7
A 0.1% by mass methanol solution of copolymer (1) was spin coated onto a PET film (1 cm × 1 cm) at room temperature. Specifically, 30 μL of the above solution was dropped on a PET film and rotated at 200 rpm for 10 seconds. Then, it dried under reduced pressure with the rotary vacuum pump at room temperature, and obtained the coating film. Further, the coated PET film was cut into 0.5 cm × 0.5 cm to obtain a coating film (a coating film formed on the surface of the PET film). About the obtained coating film | membrane, the antithrombogenicity (30 minutes) was evaluated with the following method. The results are shown in Table 5.
〔血小板粘着性及び血小板の活性化(30分間)〕
得られたコーティング膜を直径3.3cmの秤量瓶の底に少量のシリコン接着剤で固定した。これを純水で3回洗浄後、リン酸塩緩衝生理食塩液(PBS)に12時間浸漬した。PBSを除いた後、PBSで3倍希釈した0.1%クエン酸ナトリウムを含む多血小板血漿(PRP、血小板数:2×105個/μL)を上記秤量瓶に2.0mL加え、37℃で30分間静置した。PRPを除き、PBSでコーティング膜を3回洗浄した。2%グルタルアルデヒドを含むPBSを加え4℃で2時間静置し、コーティング膜表面に粘着した血小板を固定化した。サンプルをPBSで3回、純水で1回洗浄し、1晩減圧乾燥を行った。得られたサンプルを金スパッタ装置で金コートし、走査型電子顕微鏡を用いてコーティング膜表面を倍率400倍で5視野任意に観察し、粘着した血小板数をカウントした。粘着した血小板の活性化が抑制され血小板形態が球状の場合(−)、わずかに偽足化または偏平化の場合(±)、明らかな偽足化または偏平化の場合(+)、明らかな偽足化または偏平化があり血小板同士の凝集が認められた場合(++)とした。[Platelet adhesion and platelet activation (30 minutes)]
The obtained coating film was fixed to the bottom of a weighing bottle having a diameter of 3.3 cm with a small amount of silicon adhesive. This was washed 3 times with pure water and then immersed in phosphate buffered saline (PBS) for 12 hours. After removing PBS, 2.0 mL of platelet-rich plasma (PRP, platelet count: 2 × 10 5 / μL) containing 0.1% sodium citrate diluted 3-fold with PBS was added to the weighing bottle at 37 ° C. For 30 minutes. PRP was removed and the coating membrane was washed 3 times with PBS. PBS containing 2% glutaraldehyde was added and allowed to stand at 4 ° C. for 2 hours to immobilize platelets adhered to the coating film surface. The sample was washed 3 times with PBS and once with pure water, and dried under reduced pressure overnight. The obtained sample was gold-coated with a gold sputtering apparatus, and the coating film surface was observed arbitrarily at 5 magnifications using a scanning electron microscope at a magnification of 400 times, and the number of adhered platelets was counted. Adherent platelet activation is suppressed and platelet morphology is spherical (-), slightly pseudopodized or flattened (±), apparent pseudopodized or flattened (+), apparent pseudofake It was set as the case (++) when there was flocculation or flattening and aggregation of platelets was observed.
実施例8
実施例7と同様の方法で共重合体(2)のコーティング膜を得た。得られたコーティング膜について実施例7と同様の方法で抗血栓性(30分間)を評価した。結果を表5に示す。Example 8
A coating film of copolymer (2) was obtained in the same manner as in Example 7. The obtained coating film was evaluated for antithrombogenicity (30 minutes) in the same manner as in Example 7. The results are shown in Table 5.
比較例4
実施例7で用いたものと同様のPETフィルム(コーティング無)について実施例7と同様の方法で抗血栓性(30分間)を評価した。結果を表5に示す。Comparative Example 4
Anti-thrombogenicity (30 minutes) was evaluated in the same manner as in Example 7 for the same PET film (no coating) used in Example 7. The results are shown in Table 5.
実施例9
共重合体(1)の0.1質量%メタノール溶液を室温でPETフィルム(1.0cm×1.0cm)上へスピンコートした。具体的には、上記溶液30μLをPETフィルム上に滴下し、60秒間、2000rpm回転させた。その後、室温にて3時間、ロータリー真空ポンプにて減圧乾燥し、コーティング膜を得た。得られたコーティング膜について、以下の方法で細胞の接着試験を評価した。結果を表6に示す。Example 9
A 0.1 mass% methanol solution of the copolymer (1) was spin-coated on a PET film (1.0 cm × 1.0 cm) at room temperature. Specifically, 30 μL of the above solution was dropped on a PET film and rotated at 2000 rpm for 60 seconds. Then, it dried under reduced pressure with the rotary vacuum pump at room temperature for 3 hours, and obtained the coating film. About the obtained coating film | membrane, the cell adhesion test was evaluated with the following method. The results are shown in Table 6.
〔細胞接着試験〕
PETフィルム(1.0cm×1.0cm)上に共重合体(1)をスピンコートしたコーティング膜を24穴の細胞培養プレートの底に少量のシリコン接着剤で固定した。超純水で3回洗浄した後に37℃環境下のPBS中で12時間浸漬させた。[Cell adhesion test]
A coating film obtained by spin-coating the copolymer (1) on a PET film (1.0 cm × 1.0 cm) was fixed to the bottom of a 24-well cell culture plate with a small amount of silicon adhesive. After washing with ultrapure water 3 times, it was immersed in PBS at 37 ° C. for 12 hours.
マウス繊維芽細胞(NIH3T3)を5%CO2、37℃環境下で10%ウシ胎児血清(FCS)を含有するダルベッコ改変イーグル培地(FCS含有DMEM)中で培養した。培養したNIH3T3細胞を滅菌PBSで一回洗浄し、1mLの0.02% エチレンジアミン四酢酸(EDTA)溶液と1mLの0.25%トリプシン溶液を加え細胞培養プレートから剥がした。その細胞懸濁液を遠心してNIH3T3細胞を回収した後、FCS含有DMEMで再懸濁し61.2×104個/mLの溶液を得た。Mouse fibroblasts (NIH3T3) were cultured in Dulbecco's modified Eagle medium (FCS-containing DMEM) containing 10% fetal calf serum (FCS) in an environment of 5% CO 2 and 37 ° C. The cultured NIH3T3 cells were washed once with sterile PBS, 1 mL of 0.02% ethylenediaminetetraacetic acid (EDTA) solution and 1 mL of 0.25% trypsin solution were added, and the cells were detached from the cell culture plate. The cell suspension was centrifuged to collect NIH3T3 cells, and then resuspended in FCS-containing DMEM to obtain a solution of 61.2 × 10 4 cells / mL.
細胞懸濁液は、コーティング膜を固定した細胞培養プレートの各ウェルに対して1×104個/cm2に培地で調製し、コーティング膜上に播種した。5%CO2、37℃環境下で1時間培養した後、コーティング膜をPBSで3回洗浄し、4%パラホルムアルデヒド PBS溶液を用いてコーティング膜上の接着細胞を固定化した。超純水で3回洗浄した後、ロータリー真空ポンプにて減圧乾燥した。1質量%濃度のクリスタルバイオレット PBS染色液で接着細胞を染色し、光学顕微鏡を用いて5視野任意に観察を行い接着細胞の数を数えた。The cell suspension was prepared in a medium at 1 × 10 4 cells / cm 2 for each well of the cell culture plate on which the coating membrane was fixed, and seeded on the coating membrane. After culturing in an environment of 5% CO 2 and 37 ° C. for 1 hour, the coating membrane was washed three times with PBS, and adherent cells on the coating membrane were immobilized using 4% paraformaldehyde PBS solution. After washing with ultrapure water three times, it was dried under reduced pressure with a rotary vacuum pump. Adherent cells were stained with a crystal violet PBS staining solution with a concentration of 1% by mass, and the number of adherent cells was counted by arbitrarily observing 5 visual fields using an optical microscope.
実施例10
実施例9と同様の方法で共重合体(2)のコーティング膜を得た。得られたコーティング膜について実施例9と同様の方法で細胞接着試験を実施した。結果を表6に示す。Example 10
A coating film of copolymer (2) was obtained in the same manner as in Example 9. The resulting coating film was subjected to a cell adhesion test in the same manner as in Example 9. The results are shown in Table 6.
比較例5
実施例9で用いたものと同様のPETフィルム(コーティング無)について、実施例9と同様の方法で細胞接着試験を実施した。結果を表6に示す。Comparative Example 5
For the same PET film (without coating) as used in Example 9, a cell adhesion test was performed in the same manner as in Example 9. The results are shown in Table 6.
実施例11
共重合体(1)の0.1質量%メタノール溶液を室温でPETフィルム(1cm×1cm)上へスピンコートした。具体的には、上記溶液30μLをPETフィルム上に滴下し2000rpmで60秒間回転した。その後、室温にて、ロータリー真空ポンプにて減圧乾燥し、コーティング膜(PETフィルムの表面に形成されたコーティング膜)を得た。Example 11
A 0.1% by mass methanol solution of copolymer (1) was spin coated onto a PET film (1 cm × 1 cm) at room temperature. Specifically, 30 μL of the above solution was dropped on a PET film and rotated at 2000 rpm for 60 seconds. Then, it dried under reduced pressure with the rotary vacuum pump at room temperature, and obtained the coating film (coating film formed in the surface of PET film).
得られたコーティング膜について、以下の方法で大腸菌の接着性を評価した。結果を表7に示す。 About the obtained coating film | membrane, the adhesiveness of colon_bacillus | E._coli was evaluated with the following method. The results are shown in Table 7.
〔大腸菌の接着性:化学発光法による定量〕
得られたコーティング膜を24穴細胞培養ディッシュの底に少量のシリコン接着剤で固定した。これを純水で3回洗浄後、リン酸塩緩衝生理食塩液(PBS)に12時間浸漬した。PBSを除いた後、対数増殖期にある大腸菌(E.coli ATCC(R) 25922TM)を含む10質量% Muller−Hinton II (MH)培地でOD600=0.003に調製した分散液を上記細胞培養ディッシュに2.0mL加え、37℃で20時間静置培養した。上清を96穴の細胞培養ディッシュに100μLずつ加え、OD590を測定し大腸菌分散液の濃度を求めた。大腸菌が接着したコーティング膜は、24穴細胞培養ディッシュから取り出し、PBSで3回洗浄した後に新しい24穴細胞培養ディッシュに移した。接着した大腸菌の定量はBacTiter−GloTM Microbial Cell Viability Assayを用いて行った。10% BacTiter−GloTM Reagent水溶液500μLを大腸菌が接着したコーティング膜に添加し、5分間室温で静置した。その後、添加した水溶液を化学発光用96穴マイクロプレートに100μLずつ加え、プレートリーダーを用いて化学発光強度を測定した。[Adhesiveness of E. coli: quantification by chemiluminescence method]
The obtained coating film was fixed to the bottom of a 24-well cell culture dish with a small amount of silicon adhesive. This was washed 3 times with pure water and then immersed in phosphate buffered saline (PBS) for 12 hours. After removing PBS, a dispersion prepared by OD 600 = 0.003 in a 10% by mass Muller-Hinton II (MH) medium containing E. coli ATCC (R) 25922 ™ in the logarithmic growth phase was prepared as above. 2.0 mL was added to the cell culture dish, and static culture was performed at 37 ° C. for 20 hours. 100 μL each of the supernatant was added to a 96-well cell culture dish, and OD590 was measured to determine the concentration of the E. coli dispersion. The coating film to which E. coli adhered was removed from the 24-well cell culture dish, washed 3 times with PBS, and then transferred to a new 24-well cell culture dish. The quantification of the adhered E. coli was performed using BacTiter-Glo ™ Microbial Cell Viability Assay. 500 μL of 10% BacTiter-Glo ™ Reagent aqueous solution was added to the coating film to which Escherichia coli had adhered, and left at room temperature for 5 minutes. Thereafter, 100 μL of the added aqueous solution was added to a 96-well microplate for chemiluminescence, and the chemiluminescence intensity was measured using a plate reader.
〔接着大腸菌のコロニー形成:SEM観察〕
得られたコーティング膜を24穴細胞培養ディッシュの底に少量のシリコン接着剤で固定した。これを純水で3回洗浄後、リン酸塩緩衝生理食塩液(PBS)に12時間浸漬した。PBSを除いた後、対数増殖期にある大腸菌(E.coli ATCC(R) 25922TM)を含む10質量% Muller−Hinton II (MH)培地でOD600=0.003に調製した分散液を上記細胞培養ディッシュに2.0mL加え、37℃で20時間静置培養した。上清を除き、PBSでコーティング膜を3回洗浄した。2%グルタルアルデヒドを含むPBSを加え4℃で2時間静置し、コーティング膜表面に接着した大腸菌を固定化した。サンプルをPBSで3回、純水で1回洗浄し、1晩減圧乾燥を行った。得られたサンプルを金スパッタ装置で金コートし、走査型電子顕微鏡を用いてコーティング膜表面を倍率400倍及び2500倍で3視野任意に観察し、大腸菌の接着性、コロニー形成を評価した。大腸菌のコロニー形成が全く確認できないものを−、大腸菌数が400cells未満の小さなコロニーが分散して存在するもの±、大腸菌数が400cells以上の大きなコロニーが存在するものを+、大腸菌数が400cells以上の大きなコロニーが存在し、かつ広範囲にコロニー形成が広がっているものを++と表7に記す。[Colony formation of adherent E. coli: SEM observation]
The obtained coating film was fixed to the bottom of a 24-well cell culture dish with a small amount of silicon adhesive. This was washed 3 times with pure water and then immersed in phosphate buffered saline (PBS) for 12 hours. After removing PBS, a dispersion prepared by OD 600 = 0.003 in a 10% by mass Muller-Hinton II (MH) medium containing E. coli ATCC (R) 25922 ™ in the logarithmic growth phase was prepared as above. 2.0 mL was added to the cell culture dish, and static culture was performed at 37 ° C. for 20 hours. The supernatant was removed and the coating membrane was washed 3 times with PBS. PBS containing 2% glutaraldehyde was added and allowed to stand at 4 ° C. for 2 hours to immobilize E. coli adhering to the coating membrane surface. The sample was washed 3 times with PBS and once with pure water, and dried under reduced pressure overnight. The obtained sample was gold-coated with a gold sputtering apparatus, and the coating film surface was observed arbitrarily at three magnifications of 400 and 2500 using a scanning electron microscope to evaluate the adhesion and colony formation of E. coli. Those in which colony formation of E. coli could not be confirmed at all-Small colonies with an E. coli number of less than 400 cells dispersed ±, those with a large colony with an E. coli number of 400 cells or more +, E. coli number of 400 cells or more Table 7 shows the cases where large colonies exist and the colony formation spreads widely.
実施例12
実施例11と同様の方法で共重合体(2)のコーティング膜を得た。得られたコーティング膜について実施例11と同様の方法で大腸菌の接着性および接着大腸菌のコロニー形成を評価した。結果を表7に示す。Example 12
A coating film of copolymer (2) was obtained in the same manner as in Example 11. The obtained coating film was evaluated in the same manner as in Example 11 for the adhesion of Escherichia coli and colony formation of the adherent E. coli. The results are shown in Table 7.
比較例6
実施例11で用いたものと同様のPETフィルム(コーティング無)について、実施例11と同様の方法で大腸菌の接着性および接着大腸菌のコロニー形成を評価した。結果を表7に示す。Comparative Example 6
The same PET film (without coating) as used in Example 11 was evaluated for the adhesion of Escherichia coli and colonization of adherent E. coli by the same method as in Example 11. The results are shown in Table 7.
実施例11、実施例12、比較例6で得られた接着大腸菌のSEM写真を図1〜6に示す。 SEM photographs of the adherent E. coli obtained in Example 11, Example 12, and Comparative Example 6 are shown in FIGS.
製造例3
テトラフルオロエチレンとN−ビニルピロリドンの共重合体(3)の調製
気密検査済みの耐圧性反応容器内を十分に窒素置換した後、脱酸素処理したアセトン(890g)及びN−ビニルピロリドン(NVP)(60.1g)を添加した。続いてテトラフルオロエチレン(TFE)(74g)を加圧添加し、攪拌しながら混合物の内温を60℃となる様に調整した上で、t−ブチルパーオキシピバレート(2.6g)を加えて反応を開始した。反応圧の低下に応じて、TFEとNVPを追加仕込みをおこない、圧が一定になるようにした。追加仕込みしたTFEは合計91g、NVPは200gであった。反応開始から218分後、残存するTFEを除去し、反応を完了させた。次いで反応混合物を精製、乾燥させ、目的の共重合体(3)を1284g得た。得られた共重合体(3)は、重量平均分子量4.3×104、分子量分布1.9、35モル%のTFE単位及び65モル%のNVP単位を含む共重合体であることが分かった。Production Example 3
Preparation of copolymer (3) of tetrafluoroethylene and N-vinylpyrrolidone The inside of the pressure-resistant reaction vessel that had been subjected to airtightness inspection was sufficiently purged with nitrogen, and then deoxygenated acetone (890 g) and N-vinylpyrrolidone (NVP) (60.1 g) was added. Subsequently, tetrafluoroethylene (TFE) (74 g) was added under pressure, the internal temperature of the mixture was adjusted to 60 ° C. while stirring, and t-butyl peroxypivalate (2.6 g) was added. The reaction started. As the reaction pressure decreased, TFE and NVP were additionally charged to keep the pressure constant. The TFE added additionally was 91 g in total, and NVP was 200 g. 218 minutes after the start of the reaction, the remaining TFE was removed to complete the reaction. The reaction mixture was then purified and dried to obtain 1284 g of the desired copolymer (3). The obtained copolymer (3) was found to be a copolymer comprising a weight average molecular weight of 4.3 × 10 4 , a molecular weight distribution of 1.9, 35 mol% of TFE units and 65 mol% of NVP units. It was.
製造例4
テトラフルオロエチレンとN−ビニルピロリドンの共重合体(4)の調製
製造例3と同じ条件で重合をおこなった。ただし、追加仕込みしたTFEは合計88g、NVPは188gであった。反応開始から214分後、残存するTFEを除去し、反応を完了させた。次いで反応混合物を精製、乾燥させ、目的の共重合体(4)を1273g得た。得られた共重合体(4)は、重量平均分子量4.5×104、分子量分布1.9、37モル%のTFE単位及び63モル%のNVP単位を含む共重合体であることが分かった。Production Example 4
Preparation of copolymer (4) of tetrafluoroethylene and N-vinylpyrrolidone Polymerization was carried out under the same conditions as in Production Example 3. However, TFE added additionally was 88 g in total, and NVP was 188 g. 214 minutes after the start of the reaction, the remaining TFE was removed to complete the reaction. Next, the reaction mixture was purified and dried to obtain 1273 g of the desired copolymer (4). The obtained copolymer (4) was found to be a copolymer containing a weight average molecular weight of 4.5 × 10 4 , a molecular weight distribution of 1.9, 37 mol% of TFE units and 63 mol% of NVP units. It was.
製造例5
ヘキサフルオロプロピレンとN−ビニルピロリドンの共重合体(5)の調製
気密検査済みの耐圧性反応容器内を十分に窒素置換した後、脱酸素処理したアセトン(890g)及びN−ビニルピロリドン(NVP)(135g)を添加した。続いてヘキサフルオロプロピレン(HFP)(147g)を加圧添加し、撹拌しながら混合物の内温を60℃となる様に調整した上で、t−ブチルパーオキシピバレート(2.2g)を加えて反応を開始した。反応開始から164分後、残存するヘキサフルオロプロピレンを除去し、反応を完了させた。次いで反応混合物を精製、乾燥させ、目的の共重合体(5)を1157g得た。得られた共重合体(5)は、重量平均分子量1.1×104、分子量分布1.7、29モル%のHFP単位及び71モル%のNVP単位を含む共重合体であることが分かった。Production Example 5
Preparation of Copolymer (5) of Hexafluoropropylene and N-Vinylpyrrolidone After the inside of the pressure-resistant reaction vessel that has been subjected to airtightness inspection was sufficiently substituted with nitrogen, deoxygenated acetone (890 g) and N-vinylpyrrolidone (NVP) (135 g) was added. Subsequently, hexafluoropropylene (HFP) (147 g) was added under pressure, the internal temperature of the mixture was adjusted to 60 ° C. while stirring, and t-butyl peroxypivalate (2.2 g) was added. The reaction started. After 164 minutes from the start of the reaction, the remaining hexafluoropropylene was removed to complete the reaction. The reaction mixture was then purified and dried to obtain 1157 g of the desired copolymer (5). The obtained copolymer (5) was found to be a copolymer containing a weight average molecular weight of 1.1 × 10 4 , a molecular weight distribution of 1.7, 29 mol% of HFP units and 71 mol% of NVP units. It was.
製造例6
トリフルオロクロロエチレンとN−ビニルピロリドンの共重合体(6)の調製
気密検査済みの耐圧性反応容器内を十分に窒素置換した後、脱酸素処理したアセトン(751g)及びN−ビニルピロリドン(26.0g)を添加した。続いてトリフルオロクロロエチレン(116g)を加圧添加し、攪拌しながら混合物の内温を60℃となる様に調整した上で、t−ブチルパーオキシピバレート(1.8g)を加えて反応を開始した。反応開始から120分後、残存するトリフルオロクロロエチレンを除去し、ヒドロキノン(1.1g)を添加した。次いで反応混合物を精製、乾燥させ、目的の共重合体(6)を3g得た。得られた共重合体(6)は、重量平均分子量4.7×104、分子量分布4.3、64モル%のトリフルオロクロロエチレン単位及び36モル%のN−ビニルピロリドン単位を含む共重合体であることが分かった。Production Example 6
Preparation of Copolymer (6) of Trifluorochloroethylene and N-Vinylpyrrolidone The inside of the pressure-resistant reaction vessel that had been subjected to airtightness inspection was sufficiently purged with nitrogen, and then deoxygenated acetone (751 g) and N-vinylpyrrolidone (26 0.0 g) was added. Subsequently, trifluorochloroethylene (116 g) was added under pressure, and the internal temperature of the mixture was adjusted to 60 ° C. while stirring, and then t-butyl peroxypivalate (1.8 g) was added to react. Started. 120 minutes after the start of the reaction, the remaining trifluorochloroethylene was removed, and hydroquinone (1.1 g) was added. Subsequently, the reaction mixture was purified and dried to obtain 3 g of the desired copolymer (6). The obtained copolymer (6) has a weight average molecular weight of 4.7 × 10 4 , a molecular weight distribution of 4.3, a copolymer weight containing 64 mol% of trifluorochloroethylene units and 36 mol% of N-vinylpyrrolidone units. It turned out to be a coalescence.
実施例13〜16及び比較例7
BSA吸着量評価実験
製造例3〜6でえられた共重合体に関し、タンパク質吸着試験(ウシ血清アルブミン)をおこなった。Examples 13 to 16 and Comparative Example 7
BSA adsorption amount evaluation experiment A protein adsorption test (bovine serum albumin) was performed on the copolymers obtained in Production Examples 3 to 6.
共重合体(3)〜(6)およびPVDFをジメチルアセトアミド溶液に溶解させ、1質量%のポリマー溶液とした。このポリマー溶液をQCMチップであるAuセンサー(円盤状、直径1.4cm)表面に1滴垂らし、2000rpmで30秒スピンコートを行った。このセンサーを80℃、真空中で3時間乾燥させ、共重合体(3)〜(6)又はPVDFで表面がコーティングされたセンサーを作製した。この作製したセンサーをQCMにセットし、0.1M PBS(リン酸緩衝液)に溶解させた100ppm ウシ血清アルブミン(BSA)を供給することで吸着挙動を測定した。 Copolymers (3) to (6) and PVDF were dissolved in a dimethylacetamide solution to obtain a 1% by mass polymer solution. One drop of this polymer solution was dropped on the surface of an Au sensor (disk shape, diameter 1.4 cm) as a QCM chip, and spin coating was performed at 2000 rpm for 30 seconds. This sensor was dried at 80 ° C. in vacuum for 3 hours to prepare a sensor whose surface was coated with the copolymers (3) to (6) or PVDF. The produced sensor was set in QCM, and the adsorption behavior was measured by supplying 100 ppm bovine serum albumin (BSA) dissolved in 0.1 M PBS (phosphate buffer).
コーティング膜に吸着したタンパク質量は、実験から得られた吸着時間30分後の周波数を解析ソフトQToolsに導入されているSauerbreyの式からAreal mass[ng/cm2]の解析を行い算出した。The amount of protein adsorbed on the coating film was calculated by analyzing the real mass [ng / cm 2 ] from the Sauerbrey equation introduced in the analysis software QTools, based on the frequency after 30 minutes of adsorption time obtained from the experiment.
結果は、比較例7の値を100として表8に示す。 The results are shown in Table 8 with the value of Comparative Example 7 being 100.
比較としてダイキン工業社製ポリフッ化ビニリデン(PVDF) VW410を用いた。 For comparison, polyvinylidene fluoride (PVDF) VW410 manufactured by Daikin Industries, Ltd. was used.
製造例7
テトラフルオロエチレンとN−ビニルピロリドンの共重合体(7)の調製
気密検査済みの耐圧性反応容器内を十分に窒素置換した後、脱酸素処理したアセトン(890g)及びN−ビニルピロリドン(NVP)(36.0g)を添加した。続いてテトラフルオロエチレン(TFE)(131g)を加圧添加し、攪拌しながら混合物の内温を60℃となる様に調整した上で、t−ブチルパーオキシピバレート(2.6g)を加えて反応を開始した。反応圧の低下に応じて、TFEとNVPを追加仕込みをおこない、圧が一定になるようにした。追加仕込みしたTFEは合計90g、NVPは100gであった。反応開始から5時間後、残存するTFEを除去し、反応を完了させた。次いで反応混合物を精製、乾燥させ、目的の共重合体(7)を229g得た。得られた共重合体(7)は、重量平均分子量5.0×104、分子量分布2.0、46モル%のTFE単位及び54モル%のNVP単位を含む共重合体であることが分かった。Production Example 7
Preparation of copolymer (7) of tetrafluoroethylene and N-vinylpyrrolidone The inside of the pressure-resistant reaction vessel that had been subjected to airtightness inspection was sufficiently purged with nitrogen, and then deoxygenated acetone (890 g) and N-vinylpyrrolidone (NVP) (36.0 g) was added. Subsequently, tetrafluoroethylene (TFE) (131 g) was added under pressure, and the internal temperature of the mixture was adjusted to 60 ° C. while stirring, and t-butyl peroxypivalate (2.6 g) was added. The reaction started. As the reaction pressure decreased, TFE and NVP were additionally charged to keep the pressure constant. The TFE added additionally was 90 g in total, and NVP was 100 g. After 5 hours from the start of the reaction, the remaining TFE was removed to complete the reaction. Next, the reaction mixture was purified and dried to obtain 229 g of the desired copolymer (7). The obtained copolymer (7) was found to be a copolymer containing a weight average molecular weight of 5.0 × 10 4 , a molecular weight distribution of 2.0, 46 mol% of TFE units and 54 mol% of NVP units. It was.
実施例17〜19
実施例1と同様にQCM−Dを用いて、表9に記載したように、共重合体(5)、(3)、又は(7)について、ウシ血漿フィブリノーゲン(BPF)の吸着を評価した。実験の結果を表9に示す。結果は比較例2の値を100として表9に示す。Examples 17-19
As described in Table 9, the adsorption of bovine plasma fibrinogen (BPF) was evaluated for the copolymer (5), (3), or (7) using QCM-D as in Example 1. The results of the experiment are shown in Table 9. The results are shown in Table 9 with the value of Comparative Example 2 being 100.
実施例20〜22
実施例1と同様にQCM−Dを用いて、表10に記載したように、共重合体(5)、(3)、又は(7)について、グロブリン(IgG)の吸着を評価した。実験の結果を表10に示す。結果は比較例3の値を100として表10に示す。Examples 20-22
As described in Table 10, the adsorption of globulin (IgG) was evaluated for the copolymer (5), (3), or (7) using QCM-D as in Example 1. The results of the experiment are shown in Table 10. The results are shown in Table 10 with the value of Comparative Example 3 being 100.
Claims (11)
前記フルオロポリマーは、フルオロオレフィンとアミド結合を有する重合性ビニル化合物との共重合体であり、フルオロオレフィン単位が65〜5モル%であり、アミド結合を有する重合性ビニル化合物単位が35〜95モル%である
ことを特徴とする生体適合性材料。A biocompatible material comprising a fluoropolymer,
The fluoropolymer is a copolymer of a fluoroolefin and a polymerizable vinyl compound having an amide bond, the fluoroolefin unit is 65 to 5 mol%, and the polymerizable vinyl compound unit having an amide bond is 35 to 95 mol. % Biocompatible material characterized by%.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015121356 | 2015-06-16 | ||
JP2015121356 | 2015-06-16 | ||
PCT/JP2016/067907 WO2016204217A1 (en) | 2015-06-16 | 2016-06-16 | Biocompatible material, coating composition, coating film, and article |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021016373A Division JP7123346B2 (en) | 2015-06-16 | 2021-02-04 | Biocompatible materials, coating compositions, coating films and articles |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016204217A1 true JPWO2016204217A1 (en) | 2018-04-05 |
JP6889824B2 JP6889824B2 (en) | 2021-06-18 |
Family
ID=57545345
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017525289A Active JP6889824B2 (en) | 2015-06-16 | 2016-06-16 | Biocompatible materials, coating compositions, coating films and articles |
JP2021016373A Active JP7123346B2 (en) | 2015-06-16 | 2021-02-04 | Biocompatible materials, coating compositions, coating films and articles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021016373A Active JP7123346B2 (en) | 2015-06-16 | 2021-02-04 | Biocompatible materials, coating compositions, coating films and articles |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP6889824B2 (en) |
WO (1) | WO2016204217A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112280103A (en) * | 2020-10-29 | 2021-01-29 | 巢湖学院 | Antibacterial packaging film and preparation method thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3778859A4 (en) * | 2018-04-09 | 2021-04-14 | Cyfuse Biomedical K.K. | Device for maintaining culture of tubular cell structure and auxiliary tool for maintaining tubular cell structure |
WO2020054210A1 (en) | 2018-09-14 | 2020-03-19 | ダイキン工業株式会社 | Composition and multilayer body |
DE102019102597A1 (en) | 2019-02-01 | 2020-08-06 | DC Diagnostics Concept UG (haftungsbeschränkt) | Container for storing a body fluid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502781A (en) * | 1990-10-05 | 1994-03-31 | ユニヴァーシティ オブ フロリダ | Surface-modified surgical instruments, instruments, implants, contact lenses and the like |
JPH08501262A (en) * | 1993-07-27 | 1996-02-13 | ターゲット セラピューティクス,インコーポレイテッド | Metal pretreatment method for polymer coating |
JP2008511733A (en) * | 2004-08-31 | 2008-04-17 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Polymers of fluorinated monomers and hydrophilic monomers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8668919B2 (en) | 2009-03-03 | 2014-03-11 | Abbott Cardiovascular Systems Inc. | Polymer for creating hemocompatible surface |
-
2016
- 2016-06-16 JP JP2017525289A patent/JP6889824B2/en active Active
- 2016-06-16 WO PCT/JP2016/067907 patent/WO2016204217A1/en active Application Filing
-
2021
- 2021-02-04 JP JP2021016373A patent/JP7123346B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502781A (en) * | 1990-10-05 | 1994-03-31 | ユニヴァーシティ オブ フロリダ | Surface-modified surgical instruments, instruments, implants, contact lenses and the like |
JPH08501262A (en) * | 1993-07-27 | 1996-02-13 | ターゲット セラピューティクス,インコーポレイテッド | Metal pretreatment method for polymer coating |
JP2008511733A (en) * | 2004-08-31 | 2008-04-17 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Polymers of fluorinated monomers and hydrophilic monomers |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF APPLIED POLYMER SCIENCE, vol. 24, no. 3, JPN6016032350, 1979, pages 771 - 780, ISSN: 0004379336 * |
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 11, no. 3, JPN6016032349, 1977, pages 317 - 337, ISSN: 0004379335 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112280103A (en) * | 2020-10-29 | 2021-01-29 | 巢湖学院 | Antibacterial packaging film and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2016204217A1 (en) | 2016-12-22 |
JP7123346B2 (en) | 2022-08-23 |
JP2021091908A (en) | 2021-06-17 |
JP6889824B2 (en) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7123346B2 (en) | Biocompatible materials, coating compositions, coating films and articles | |
US10669445B2 (en) | Ion complex material having function of inhibiting adhesion of biological substance and method for manufacturing the same | |
Bakirci et al. | Cell sheet based bioink for 3D bioprinting applications | |
Carr et al. | Engineering the polymer backbone to strengthen nonfouling sulfobetaine hydrogels | |
US20170260497A1 (en) | Thermoresponsive cell culture supports | |
JP6810386B2 (en) | Low protein adsorptive material, low protein adsorptive article, low cell adhesion material and low cell adhesion article | |
Bruil et al. | In vitro leucocyte adhesion to modified polyurethane surfaces: I. effect of ionizable functional groups | |
EP2173857A1 (en) | Cell culture substrate | |
Iwasaki et al. | Selective biorecognition and preservation of cell function on carbohydrate-immobilized phosphorylcholine polymers | |
JP2015180723A (en) | Polymer base material, use thereof and method of producing the same | |
Xu et al. | Polyurethane/Dermatan Sulfate Copolymers as Hemocompatible, Non‐Biofouling Materials | |
EP3719113A1 (en) | Cell culture container capable of long-term culture, and method for manufacturing same | |
Giol et al. | Biomimetic strategy towards gelatin coatings on PET. Effect of protocol on coating stability and cell-interactive properties | |
Healy et al. | Nanometer-scale physically adsorbed thermoresponsive films for cell culture | |
Bittrich et al. | Control of Protein Adsorption and Cell Adhesion by Mixed Polymer Brushes Made by the “Grafting-To” Approach | |
Chou et al. | Zwitterionic Surface Modification of Aldehydated Sulfobetaine Copolymers for the Formation of Bioinert Interfaces | |
US6365692B1 (en) | Preparation of carboxylate-sulfonate polymers having cell proliferation-promoting properties | |
US20200291339A1 (en) | Cell culture container having minute volume | |
JP2018123275A (en) | Cell adhesion inhibitor | |
TW201602260A (en) | Ion complex material having function for preventing adherence to biological material | |
Sun et al. | Fast-polymerized lubricant and antibacterial hydrogel coatings for medical catheters | |
US11246966B2 (en) | Copolymer-comprising antimicrobial, cell culture, antithrombotic, or biopharmaceutical article | |
US20230392037A1 (en) | Biological substance low adhesion material comprising copolymer | |
WO2020166605A1 (en) | Method for producing polymer compatible with biomaterials | |
Han et al. | Grafting zwitterionic brushes from the surface of an epoxy-based transparent hydrogel for antifouling performance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20171226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200331 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200716 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210204 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210204 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210216 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210420 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210428 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6889824 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |